Pushkal Garg - Dec 12, 2024 Form 4 Insider Report for ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Signature
By: Brett Budzinski, Attorney-in-Fact For: Pushkal Garg
Stock symbol
ALNY
Transactions as of
Dec 12, 2024
Transactions value $
-$439,760
Form type
4
Date filed
12/13/2024, 04:13 PM
Previous filing
Nov 27, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALNY Common Stock Sale -$29.9K -121 -0.69% $247.48 17.3K Dec 12, 2024 Direct F1
transaction ALNY Common Stock Sale -$46.3K -186 -1.07% $248.99 17.2K Dec 12, 2024 Direct F1, F2
transaction ALNY Common Stock Sale -$107K -426 -2.48% $250.08 16.7K Dec 12, 2024 Direct F1, F3
transaction ALNY Common Stock Sale -$196K -778 -4.65% $251.68 15.9K Dec 12, 2024 Direct F1, F4
transaction ALNY Common Stock Sale -$25.3K -100 -0.63% $252.94 15.8K Dec 12, 2024 Direct F1
transaction ALNY Common Stock Sale -$35.6K -140 -0.88% $254.37 15.7K Dec 12, 2024 Direct F1, F5
transaction ALNY Common Stock Sale -$256 -1 -0.01% $255.80 15.7K Dec 12, 2024 Direct F1
holding ALNY Common Stock 431 Dec 12, 2024 by Managed Account F6
holding ALNY Common Stock 250 Dec 12, 2024 by Trust F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 11, 2024.
F2 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $248.69 to $249.52. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $249.71 to $250.42. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $251.23 to $252.22. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F5 The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $254.35 to $255.02. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F6 Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.
F7 Represents shares held in trust, of which the Reporting Persons spouse is co-trustee. The Reporting Person disclaims beneficial ownership of these shares, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.